EBITDA down 61% and PBT loss quadrupled to $9.9m despite revenue growth

What changed

Revenue rose to $69.7m (the release cites +12% on 1H22, while the supplied prior comparable of $44.9m implies a +55.2% step-up — a discrepancy flagged in the data). Despite top-line growth, EBITDA fell 60.9% to $2.5m, the pre-tax loss widened from -$2.1m to -$9.9m, and NPAT deteriorated from -$2.8m to -$8.7m. A $1.4m tax benefit softened the bottom line; on a pre-tax basis — the cleaner read here — losses grew roughly $7.8m. Operating cash flow improved sharply to $6.2m (from $1.0m), but the cash balance declined by $21.0m to $37.1m while gross borrowings rose to $18.9m from $16.5m. Segment-wise, Cinema remains dominant at ~68% of revenue ($47.5m, inferred EBITDA margin ~16.6%), with Movio at $9.7m (~18.6%) and AGC at $12.5m (~12.0%). No interim dividend was declared.

What matters

• Profitability has broken from revenue. EBITDA fell even as revenue grew, and segment-level margins (Cinema ~16.6%, AGC ~12.0%) are materially below what a software-led recurring-revenue model would typically warrant. Management frames this as the cost of an announced "business transformation," but the release does not quantify transformation expense, so readers cannot separate underlying margin from one-off spend.
• The cash cushion is visibly thinner. Cash down $21.0m and borrowings up $2.4m compressed the net-cash position from roughly $41.6m to $18.2m. The group is still net cash, but the runway has narrowed at a time when statutory losses are widening.
• Receivables collection was a real tailwind. Trade receivables fell from $46.3m to $30.3m (receivable days roughly 79 from 188 on a 182-day basis), and this working-capital release is a meaningful contributor to the headline OCF improvement.

Expectations

No financial guidance, forward work metric, or quantitative target was disclosed in the extracted materials. Historical shape is not a useful anchor either: HY22 represented only 33.2% of FY22 revenue but 60.4% of FY22 EBITDA — a pattern distorted by the FY22 H2 loss. Annualising HY23 revenue yields ~$139.4m, only modestly above FY22's $135.1m. The release supports a view that revenue is growing and recurring-revenue mix is improving, but it does not support any read on when EBITDA recovers to levels consistent with a mid-teens-plus margin business.

Quality of result

Low durability on the earnings line; higher quality on the cash line, with caveats. The $6.2m OCF is flattered by a $16.0m reduction in trade receivables — a one-time step-down rather than a repeatable conversion pattern — and OCF at ~248% of EBITDA is a mechanical artefact rather than a sign of structural cash generation. Reported NPAT is also softened by a tax benefit of $1.4m against a larger pre-tax loss. Capex was not disclosed, so free cash flow cannot be reliably calculated. The EBITDA compression, by contrast, is genuine and not explained away by any quantified non-recurring adjustment in the supplied excerpts.

Unresolved

• How much of the HY23 EBITDA compression is transformation-related and reversible versus structural cost inflation in the operating base?
• What is capex and capitalised-development intensity, and therefore what is free cash flow once working-capital normalises?
• How much further does the cash balance fall before the transformation program self-funds, and what is the covenant/headroom position on the $18.9m of borrowings?
• Why does the company-cited revenue growth of 12% on 1H22 diverge from the 55.2% implied by the supplied prior comparable, and which is the correct base?

This briefing cannot assess underlying recurring-revenue quality, churn, or the run-rate economics of the transformation program, because the supplied extracts do not quantify transformation costs, customer metrics, or segment margin history.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.